1. Membrane Transporter/Ion Channel
    MAPK/ERK Pathway
    Stem Cell/Wnt
    NF-κB
    Apoptosis
  2. Sodium Channel
    MEK
    ERK
    NF-κB
    Apoptosis
  3. Lidocaine hydrochloride

Lidocaine hydrochloride (Synonyms: Lignocaine hydrochloride)

目录号: HY-B0185A 纯度: 99.95%
产品使用指南

Lidocaine hydrochloride (Lignocaine hydrochloride) 抑制涉及复杂电压和依赖性的钠通道 (sodium channels)。Lidocaine hydrochloride 通过调节 miR-145 表达和进一步抑制 MEK/ERKNF-κB 信号通路来减少胃癌细胞的生长,迁移和侵袭。Lidocaine hydrochloride 是一种酰胺衍生物常用于局部麻醉。Lidocaine hydrochloride 是一种治疗室性心律失常的药物和有效的肿瘤抑制剂。

MCE 的所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务

Lidocaine hydrochloride Chemical Structure

Lidocaine hydrochloride Chemical Structure

CAS No. : 73-78-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

Size Price Stock Quantity
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥500 In-stock
500 mg ¥400 In-stock
5 g ¥500 In-stock
10 g ¥800 In-stock
50 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Lidocaine hydrochloride:

Top Publications Citing Use of Products

    Lidocaine hydrochloride purchased from MCE. Usage Cited in: J Neuroinflammation. 2017 Nov 2;14(1):211.

    Immunoblot results demonstrate that Lidocaine inhibits Morphine-induced upregulation of phosphorylation of p38 MAPK, but not the p38 total protein.

    View All MEK Isoform Specific Products:

    View All ERK Isoform Specific Products:

    View All NF-κB Isoform Specific Products:

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    Description

    Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative commonly used to anesthetize. hydrochloride is a a drug to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

    IC50 & Target[1,2]

    MEK

     

    ERK

     

    NF-κB

     

    In Vitro

    Lidocaine hydrochloride (Lignocaine hydrochloride) (10 nM; 48 hours) decreases significantly cell proliferation[2].
    Lidocaine hydrochloride (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2].
    Lidocaine hydrochloride (10 nM; 48 hours) increases significantly the apoptotic cell rate[2].
    Lidocaine hydrochloride (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2].

    Cell Proliferation Assay[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Decreased significantly cell proliferation.

    Cell Viability Assay[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 1, 5 and 10 nM
    Incubation Time: 24, 48, 72 hours
    Result: Inhibited MKN45 cell viability.

    Apoptosis Analysis[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Increased significantly the apoptotic cell rate.

    Western Blot Analysis[2]

    Cell Line: The human gastric cancer cell line MKN45
    Concentration: 10 nM
    Incubation Time: 48 hours
    Result: Down-regulated Cyclin D1 and up-regulated p21 expression significantly.
    In Vivo

    Lidocaine hydrochloride (Lignocaine hydrochloride) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block[3].

    Clinical Trial
    Molecular Weight

    270.80

    Formula

    C₁₄H₂₃ClN₂O

    CAS No.

    73-78-9

    SMILES

    O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]Cl

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    H2O : ≥ 100 mg/mL (369.28 mM)

    DMSO : ≥ 100 mg/mL (369.28 mM)

    * "≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.6928 mL 18.4638 mL 36.9276 mL
    5 mM 0.7386 mL 3.6928 mL 7.3855 mL
    10 mM 0.3693 mL 1.8464 mL 3.6928 mL
    *

    请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。 -80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

    In Vivo:

    请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
    分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 1.

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (9.23 mM,饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

      将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,澄清透明的生理盐水溶液
    • 2.

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (9.23 mM,饱和度未知) 的澄清溶液。

      以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

      将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定溶至 10 mL,完全溶解,澄清透明
    • 3.

      请依序添加每种溶剂: 10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (9.23 mM); Clear solution

      此方案可获得 ≥ 2.5 mg/mL (9.23 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

      以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

    *以上所有助溶剂都可在 MCE 网站选购。
    References
    • 摩尔计算器

    • 稀释计算器

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    LidocaineLignocaineSodium ChannelMEKERKNF-κBApoptosisNa channelsNa+ channelsMitogen-activated protein kinase kinaseMAPKKMAP2KExtracellular signal regulated kinasesNuclear factor-κBNuclear factor-kappaBInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Lidocaine hydrochloride
    目录号:
    HY-B0185A
    需求量: